309 related articles for article (PubMed ID: 25755549)
21. Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response.
Sood A; Midha V; Goyal O
J Clin Exp Hepatol; 2015 Mar; 5(1):2-7. PubMed ID: 25941428
[TBL] [Abstract][Full Text] [Related]
22. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?
Anand AC
J Clin Exp Hepatol; 2017 Mar; 7(1):42-54. PubMed ID: 28348470
[TBL] [Abstract][Full Text] [Related]
23. Indian National Association for the Study of the Liver-Federation of Obstetric and Gynaecological Societies of India Position Statement on Management of Liver Diseases in Pregnancy.
Arora A; Kumar A; Anand AC; Puri P; Dhiman RK; Acharya SK; Aggarwal K; Aggarwal N; Aggarwal R; Chawla YK; Dixit VK; Duseja A; Eapen CE; Goswami B; Gujral K; Gupta A; Jindal A; Kar P; Kumari K; Madan K; Malhotra J; Malhotra N; Pandey G; Pandey U; Puri RD; Rai RR; Rao PN; Sarin SK; Sharma A; Sharma P; Shenoy KT; Singh KR; Singh SP; Suri V; Trehanpati N; Wadhawan M
J Clin Exp Hepatol; 2019; 9(3):383-406. PubMed ID: 31360030
[TBL] [Abstract][Full Text] [Related]
24. Treatment of chronic hepatitis C in Asia: when East meets West.
Yu ML; Chuang WL
J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
[TBL] [Abstract][Full Text] [Related]
25. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
26. [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
Ji F; Dang S; Cai Z; Xue H; Huang N; Liu L; Zhang S; Guo Y; Jia X; Wang Y; Li Z; Deng H
Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):647-52. PubMed ID: 26524356
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
[TBL] [Abstract][Full Text] [Related]
28. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.
Acharya SK; Sreenivas V; Gupta SD; Kumar S; Chawla YK; Tandon A; Habeeb A; Kar P; Chowdhury A; Choudhuri G; Sarin SK; Amarapurkar D; Arankalle V; Gupte MD; Gupta S; Mukherjee D; Seth D; Goyal R; Tandon BN
J Clin Exp Hepatol; 2012 Mar; 2(1):10-8. PubMed ID: 25755401
[TBL] [Abstract][Full Text] [Related]
31. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
32. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
[TBL] [Abstract][Full Text] [Related]
34. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
Corchado S; López-Cortés LF; Rivero-Juárez A; Torres-Cornejo A; Rivero A; Márquez-Coello M; Girón-González JA
PLoS One; 2014; 9(7):e101760. PubMed ID: 25013899
[TBL] [Abstract][Full Text] [Related]
35. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
36. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
37. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.
Kumar A; Acharya SK; Singh SP; Arora A; Dhiman RK; Aggarwal R; Anand AC; Bhangui P; Chawla YK; Datta Gupta S; Dixit VK; Duseja A; Kalra N; Kar P; Kulkarni SS; Kumar R; Kumar M; Madhavan R; Mohan Prasad VG; Mukund A; Nagral A; Panda D; Paul SB; Rao PN; Rela M; Sahu MK; Saraswat VA; Shah SR; Shalimar ; Sharma P; Taneja S; Wadhawan M;
J Clin Exp Hepatol; 2020; 10(1):43-80. PubMed ID: 32025166
[TBL] [Abstract][Full Text] [Related]
38. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
[TBL] [Abstract][Full Text] [Related]
40. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
